Pfizer Licenses Phase III AMD Drug from Eyetech
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 32 (Table of Contents)
Published: 3 Jan-2003
DOI: 10.3833/pdr.v2003.i32.953 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer licensed Macugen(TM) from Eyetech Pharmaceuticals for US$745 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018